AI-based complete blood count model for colorectal cancer detection.
Abstract
e15693 Background: Early colorectal cancer (CRC) detection is crucial for effective treatment; however, traditional screening methods face challenges. Colonoscopy, though effective, has limited availability, especially in resource-constrained settings. Conversely, fecal occult blood tests are cost-effective and widely available but suffer from low adherence. These barriers underscore the need for innovative approaches to support CRC screening efforts. Our retrospective study proposes developing a machine learning model based on complete blood count (CBC) tests as a risk stratification tool for CRC. By identifying high-risk individuals, this method could facilitate resource prioritization and active case-finding in at-risk populations, complementing existing screening programs and improving overall accessibility. Methods: We analyzed CBC tests from 7,588 individuals (3,990 females, 52,58%; 3,598 males, 47,42%) aged 45-75 who underwent colonoscopy or biopsies within six months of their CBC test. Among them, 468 (6,17%) were identified as cases confirmed by anatomopathological tests. The remaining 7,120 (93,83%) individuals were classified as controls, with typical colonoscopy results and without polyps, neoplasms, or other abnormalities. The database was divided into training (80%) and validation (20%) sets. The model was developed using ridge regression. Results: Descriptive analysis of all CBC biomarkers, CBC-derived ratios, and age revealed significant differences between controls and CRC cases across all features ( P < 0.001), except for lymphocytes. Using a feature selection methodology, the markers RDW, leukocytes, hemoglobin, and age were incorporated in a ridge regression model, achieving an AUC of 0.75 (95% CI: 0.74–0.75). The model was trained on a combined dataset to assess overall performance without introducing sex-based biases. It was then tested separately on male and female subsets, yielding an AUC of 0.76 (95% CI: 0.75–0.78) for males and 0.75 (95% CI: 0.74–0.75) for females, indicating consistent performance across genders. Explainability analysis revealed that increased age, higher RDW, elevated leukocyte counts, and lower hemoglobin levels were linked to a higher risk of CRC. Due to the imbalance in our dataset, we selected the threshold that maximized the balanced accuracy, resulting in a sensitivity of 0.72, specificity of 0.66, accuracy of 0.66, balanced accuracy of 0.69, negative predictive value (NPV) of 0.97, and positive predictive value (PPV) of 0.13. Conclusions: Our findings suggest that our model can contribute to the early detection of CRC, potentially serving as a valuable risk stratification tool for screening. However, the absence of external validation is a limitation of this study, requiring further research to confirm its generalizability and clinical impact.
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (11)
Daniella Araújo
HUNA, São Paulo, São Paulo, Brazil
Bruno Aragao Rocha
Fleury Group, São Paulo, São Paulo, Brazil
Bruna Los
Huna, São Paulo, Brazil
Daniel Noce da Silva
Huna, São Paulo, SP, Brazil
Vinicius Moura Ribeiro
HUNA, São Paulo, São Paulo, Brazil
Marco Aurelio Kohara
HUNA, São Paulo, São Paulo, Brazil
Maria Carolina Tostes Pintão
Otavio Jose Eulalio
Fleury Group, São Paulo, Brazil
João Vicente de Morais Malvezzi
Fleury Group, São Paulo, São Paulo, Brazil
Flavia Helena da Silva
Fleury Group, São Paulo, São Paulo, Brazil
Pedro Henrique Souza
Brazilian National Cancer Institute (INCA), Rio De Janeiro, Brazil